Abstract
Background: The PAM50 test provides important prognostic information for therapeutic decision in hormone-receptor positive (HR+) and HER2-negative (HER2-) early breast cancer. This genomic signature estimates the risk of recurrence (ROR) at 10 years, for patients treated with adjuvant hormone therapy (HT) alone. It also allows the determination of breast cancer intrinsic subtype. However, its validation results only from retrospective studies. We aimed to analyze the correlation between histopathological variables and risk of breast cancer recurrence, as well as the agreement between subtype-like, obtained by immunohistochemistry (IHC) and breast cancer intrinsic subtype, obtained through this molecular analysis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
